MichaelS.RafiiMDPhD

Neurology • San Diego, CA

Associate Professor of Neurology, Keck School of Medicine of USC

Join to view full profile

Dr. Rafii is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rafii's full profile

Already have an account?

Office
4510 Executive Dr
San Diego, CA 92121
Phone+1 858-657-8540

Fax+1 858-657-8557

Education & Training

Johns Hopkins UniversityResidency, Neurology, 2003 - 2006
Johns Hopkins UniversityInternship, Internal Medicine, 2002 - 2003
The Warren Alpert Medical School of Brown UniversityClass of 2002

Certifications & Licensure

CA State Medical License 2006 - 2026
American Board of Psychiatry and Neurology Neurology

Clinical Trials

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext Start of enrollment: 2013 Mar 01
Completed
Phase 2, Phase 3
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo Start of enrollment: 2013 Jul 01
Terminated
Phase 3
Down Syndrome Biomarker Initiative (DSBI) Start of enrollment: 2013 Jun 01
Completed
Safety, Tolerability and Immunogenicity of ACI-24 Vaccine in Adults With Down Syndrome Start of enrollment: 2016 Mar 01
Completed
Phase 1
Trial-Ready Cohort-Down Syndrome (TRC-DS) Start of enrollment: 2021 Jun 07
Recruiting
Join now to see all

Publications & Presentations

PubMed

53 citations
Early-stage Alzheimer disease: getting trial-ready.
Paul S Aisen, Gustavo A Jimenez-Maggiora, Michael S Rafii, Sarah Walter, Rema Raman
Nature Reviews. Neurology. 2022-07-01
16 citations
Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome: A Phase 1b Randomized Clinical Trial.
Michael S Rafii, Olivier Sol, William C Mobley, Saskia Delpretti, Brian G Skotko
JAMA Neurology. 2022-06-01
131 citations
Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial.
Michael S. Rafii, Mark H. Tuszynski, Ronald G. Thomas, David Barba, James B. Brewer
JAMA Neurology. 2018-07-01

Journal Articles

Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease
Reisa Sperling, Michael S Rafii, Gary Romano, JAMA Neurology

Press Mentions

Alzheimer's Meds Are Here. But for the down Syndrome Community, It's Still the 1980sMarch 1st, 2023
Top Dementia Scientists Present Key Findings, InitiativesNovember 28th, 2022
It’s Not a Normal Sign of Aging: Mild Cognitive Impairment Takes TollApril 19th, 2022
Join now to see all